Navigation Links
Regeneron to Report Second Quarter 2014 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2014
Date:7/18/2014

TARRYTOWN, N.Y., July 18, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2014 financial and operating results on Tuesday, August 5, 2014, before the U.S. financial markets open.  The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.

Conference Call InformationTo access this call, dial (888) 660-6127 (U.S.) or (973) 890-8355 (International).  A link to the webcast may be accessed from the 'Events and Presentations' page of Regeneron's website at www.regeneron.com.  A replay of the conference call and webcast will be archived on the Company's website and will be available for 30 days. 

About Regeneron PharmaceuticalsRegeneron is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron commercializes medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, asthma, and atopic dermatitis.  For additional information about the company, please visit www.regeneron.com.Contact Information:Manisha Narasimhan, Ph.D.Hala MirzaInvestor RelationsCorporate Communications 914-847-5126 

914-847-3422 manisha.narasimhan@regeneron.comhala.mirza@regeneron.com 


'/>"/>
SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Regenerons Chief Executive Officer and Chief Scientific Officer named "Management Team of the Year" by Scrip Intelligence
2. Regeneron Named Top Employer in the Global Biopharmaceutical Industry for the Second Year in a Row
3. After 18 Months On the U.S. Market, Regenerons Eylea Captures One-Fifth of First-Line Intravitreal Pharmacotherapy Share Among Wet Age-Related Macular Degeneration (AMD) Patients
4. Zacks Investment Ideas feature highlights: Market Vectors Biotech ETF, iShares Nasdaq Biotechnology ETF, Regeneron, Celgene and First Trust Amex Biotechnology Index Fund
5. Regeneron Reports First Quarter 2013 Financial and Operating Results
6. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
7. Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
8. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
9. Regeneron Announces March 2012 Investor Conference Presentations
10. Regeneron Announces Presentation at the Leerink Swann 2012 Global Healthcare Conference
11. Exelixis, Inc., Analyst Report; The Upside Potential is Worth the Risk by BrokerBank Securities, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... Inc. ("SQI" or the "Company") (TSX-V: SQD; OTCQX: SQIDF), today reported its ... ended September 30, 2016. ... , SQI is a ... develops and commercializes proprietary technologies and products for advanced multiplexed diagnostics. ... $1.4 million more than tripling prior years revenue. ...
(Date:12/6/2016)... Colorado (PRWEB) , ... December 06, 2016 , ... ... dynamic aqueous plasma technology platforms, announced today that the company has engaged in ... Research and Development Agreement (MRDA) with the CSU Office of the Vice President ...
(Date:12/6/2016)... , Dec. 6, 2016  SRI International has ... million from the National Institutes of Health,s National ... Division of AIDS (NIAID-DAIDS) to support the manufacturing ... pre-exposure (PreP) agents. Under the seven-year contract, SRI ... development services for candidate HIV-prevention products that emerge ...
(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... ... nanocellulose, including both cellulose nanocrystals and cellulose nanofibrils. The composition claims are ... There are also claims directed to combination with polymers, carbon fibers, graphene, and ...
Breaking Biology Technology:
(Date:12/6/2016)... Valencell , the leading innovator in ... a third consecutive year of triple digit growth for ... with a 360 percent increase in companies who have ... driven by sales of its wrist and ear Benchmark™ ... technology for hearables for fitness and healthcare applications. ...
(Date:12/2/2016)... December 1, 2016 The ... Voice), Future Technology (Iris Recognition System), Vehicle Type ... Global Forecast to 2021", published by MarketsandMarkets, the ... in 2016, and is projected to grow to ... of 14.06%.      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
(Date:11/30/2016)... , Nov. 30, 2016  higi SH ... new partnership initiative targeting national brands, industry thought-leaders ... reward their respective audiences for taking steps to ... its inception in 2012, higi has built the ... impacting over 38 million people who have conducted ...
Breaking Biology News(10 mins):